BLUESKY MEETING 10 octobre 2014, Centre des Congrès WTC - Grenoble - Lyonbiopole
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
BLUESKY MEETING
10 octobre 2014, Centre des Congrès WTC - Grenoble
SESSION 2
PRAGMA THERAPEUTICS MODELAST - Cell sensitivity to the elastic properties
DUVEY Guillaume - Co-founder & CSO of the extracellular matrix
NICOLAS Alice - Associate Researcher, CEA Grenoble
BIOWATTS - Biomimetic biofuel cell technology for biological
power supplies OPeRa BIOBANK - OPeRa (Organ Protection & Replacement)
MARTIN Donald – Professor, Joseph Fourier University OVIZE Michel - Pr. and coordonator, OPeRa IHU
STATIMPROVE - L-citrulline and statins: an innovative KCH - KeepCleanHands
association for treatment of obesity and type 2 diabetes KECHICHIAN Asbed - Development manager, KeepCleanHands
MORIO-LIONDORE Béatrice - Director of Research
HISTORAM - Histopathology via Raman Spectroscopy
ECOFECT - The Chimeric Mice Core Facility of ECOFECT STROLA Samy Andrea – Researcher, CEA Grenoble
NAIGLIN Laurence - Project manager
APIOS - Osteoinductive coatings
AUTONOM@DOM CROUZIER Thomas - Post-doctoral, Grenoble Institute of
SALVAT Muriel – Doctor, Grenoble University Hospital Center Technology
Guillaume DUVEY, Pragma Therapeutics PRAGMA THERAPEUTICS Developing novel therapeutics for the treatment of Post Traumatic Stress Disorders
Developing novel therapeutics for the treatment of PTSD
Context and
Context and Objectives
Objectives Description
Description
Post Traumatic Stress Disorder:
An urgent medical need
Core Symptoms
• Anxiety
• Re-experiencing
• Avoidance
• Hyperarousal
Developing novel therapeutics for the treatment of PTSD
Originalité scientifique, technique & Marchés ciblés & Retombées
Context and Objectives Description
Innovation attendues
Post Traumatic Stress Disorder: mGlu7 modulation to
An urgent medical need Improve PTSD core symptoms
Trauma
7.7 A • Fear
Millions
• Stress
USA 10% 5% • Emotion
• Memory
Psychotherapy compliance
1997 2007
Pharmacotherapy warnings Human mGlu7 First mGlu7
protein discovered blockers
Developing novel therapeutics for the treatment of PTSD
Originalité scientifique, technique & Marchés ciblés & Retombées
Context and Objectives Description
Innovation attendues
Post Traumatic Stress Disorder: mGlu7 modulation to
An urgent medical need Improve PTSD core symptoms
mGlu7 protein
7.7 A
Millions
USA 10% 5%
Psychotherapy compliance
1997 2007 2013
Pharmacotherapy warnings Human mGlu7 First mGlu7 POC in animal
protein discovered blockers model of anxiety
Restore Cognitive and Emotional
Brain functions
Developing novel therapeutics for the treatment of PTSD
Originalité scientifique,
Scientific, Technical technique
Assets / & Marchésscientific
Economic ciblés & Retombées
and technical
Innovation
Innovation attendues
impacts expected
Long-standing R&D experience in the mGlu class Weak PTSD pipeline
CAGR of 3.2%
Feature-based De Novo design of several novel
mGlu7 blockers
Market in 2019: 1.8b$
Phase II/III in
specific population
[11C]
[3H] Phase 0 concept
[18F] First human data
Target engagement in
Selection & characterization of novel mGlu7 brain the disease models
specific modulators
Oral POC in translational
2-6 patent applications to be filed in Q4-2014 animal models of PTSD
Developing novel therapeutics for the treatment of PTSD
Kind ofofpartnership
Kind intended
partnership intended Financial
Financialinstrument considered
instrument considered
International preclinical partnerships to access • BPI innovation grants
cutting-edge technologies and expertise • FUI grant through collaboration with already
identified private and academic partners
• Investigate mGlu7 signaling pathways
• ANR grant to support further development
(INSERM IGF Montpellier)
• Eurostar grant
• Develop specific stress-induced in vivo models to
characterize our molecules for PTSD treatment
(USF Florida) Contact
• Prepare and evaluate novel neuroimaging radiotracers
to study mGlu7 blockers neurolocalisation "in vivo" Guillaume.Duvey@pragmatherapeutics.com
(CERMEP Lyon / MNI New-Jersey)
www.pragmatherapeutics.com
• Investigate orphan indications for mGlu7 blockers
(undisclosed)
BLUESKY MEETING - SESSION 2
10 octobre 2014, Centre des Congrès WTC - Grenoble
Donald MARTIN, Joseph Fourier University
BIOWATTS
Biomimetic biofuel cell technology for biological
power supplies
BIOWATTS
Biomimetic biofuel cell technology for biological power supplies
Contextand
Context and Objectives
Objective Description
• aims: develop a biomimetic fuel cell (BBFC) to BBFC to
provide power for medical devices produce
biomimetic
• objectives: “power”
a) optimise biomimetic membrane for BBFC [1],
b) optimise selective transport proteins for biomimetic
membranes [2, 3],
K+
c) optimise incorporation of transport proteins into
biomimetic membrane [2, 3],
“artificial cells” cell membranes
d) engineering of biocompatible container for BBFC, e.g. use proteins to
use proteins to
for implantation into humans or animals [4] transport
transport
• context: electrolytes electrolytes
[1] Stidder et al (2012). Adv. Funct. Mater., 22:4259-67 Biomimetic fuel-cell
[2] « Biomimetic Artificial Membrane Device » Enzymatic fuel-cell
PCT/EP2008/058253
[3] Battle et al (2008). Adv. Funct. Mater., 19:201-208 apply our know-how
[4] www.ibfc.fr in biocompatibility
1 cm
BIOWATTS
Biomimetic biofuel cell technology for biological power supplies
Scientific,
ContextTechnical Assets /
and Objectives Economic scientific and technical
Description
Innovation impacts expected
good power-to-volume output, and
excellent prospects for miniaturisation
+ +
support lipid membrane ion channel • Medical device market:
… defibrillators, pacemakers, neurostimulators, muscle
stimulators, implanted remote monitoring devices,
mechanical pumps
K+
• Nomadic consumer electronics market:
functional ion transport … renewable and “green” energy… since the fuel is saltBIOWATTS
Biomimetic biofuel cell technology for biological power supplies
Kind of partnership intended Financial instrument considered
• Public funding instruments:
… national
partnership for commercial exploitation … Horizon 2020 (e.g. FET, SME actions)
… established company in medical electronic devices • Private funding:
… startup … licence, JV, high-net-worth, angel investment …
• fundamental research funded until 12/2016
… Investissement d’Avenir Contact
… core research team (SyNaBi) active within laboratory
TIMC-IMAG (www-timc.imag.fr/rubrique480.html )
• commercial exploitation could start earlier Donald MARTIN
don.martin@imag.frBLUESKY MEETING - SESSION 2
10 octobre 2014, Centre des Congrès WTC - Grenoble
Béatrice MORIO-LIONDORE, CENS; CarMeN
Laboratory and LBFA research laboratories
STATIMPROVE
L-citrulline and statins: an innovative association
for treatment of obesity and type 2 diabetesStatimprove : L-citrulline and statins: an innovative association
for treatment of obesity and type 2 diabetes
Context and Objectives Description
• Potentiating the beneficial health effects of L-arginine precursor
statins using L-citrulline Vascular Regulation of
Protein synthesis
Statins are part of the world's most-prescribed class of medications. They endothelium
are the cornerstone treatment for dyslipidemia and prevention of Antioxydant Skeletal muscle
L-citrulline
cardiovascular diseases. They lower blood cholesterol by inhibiting the Brain Regulation of Urea cycle
enzyme HMG-CoA reductase, which plays a central role in hepatic lipolysis Liver
cholesterol production.
Adipose tissue
L-citrulline is a non-protein amino acid found in cucurbits and mainly
synthesized by the intestine in animals.
• We demonstrated in a preclinical study that L-citrulline statin
potentiates the effects of statins on lipid and glucose
metabolism:
decrease of intra-abdominal fat depots NO• precursor
improvement of glucose homeostasis Polyamines precursor
inhibition of de novo lipogenesis Stimulation
Urea cycle
of immune system L-arginine Contribution to
energy production
L-citrulline is a relevant synergistic molecule to Stimulation of
Implication in
hormone secretion
potentiate beneficial health effects of statins Improvement of
collagen synthesis
Insulin sensitivityStatimprove : L-citrulline and statins: an innovative association
for treatment of obesity and type 2 diabetes
Originalité scientifique,
Scientific, Technical technique
Assets / & Marchésscientific
Economic ciblés & Retombées
and technical
Innovation
Innovation attendues
impacts expected
• A two-fold innovation • Citizen benefits
a significant step forward for the optimization Reduction of the risk factors of obesity and type 2
of statin treatment diabetes
Optimization of the beneficial metabolic effects of statins Optimization of the beneficial metabolic effects of
Intra-abdominal fat depots statins
Glucose homeostasis
Improvement of the tolerance to the treatment
Lipid homeostasis
Limitation of the statins’ side effects
• Economic impacts
an original pharmaco-nutritional therapy to prevent
from obesity and type 2 diabetes World statins market is facing rapid changes and
Potentialization of statin indirect mechanisms needs innovations
Can be enlarged to overweight and obese
Compared to L-arginine, L-citrulline offers a number of advantages for
nutritional supplementation, as it is characterized by:
populations
• an improved gastrointestinal tolerance And to patients at risks for insulin resistance and
• a better whole-body bioavailability
• a better pool-precursor for NO synthesis.
type 2 diabetesStatimprove : L-citrulline and statins: an innovative association
for treatment of obesity and type 2 diabetes
Kind ofofpartnership
Kind intended
partnership intended Financial
Financialinstrument considered
instrument considered
• Clinical partnership • PHRC or FUI consortium
• Pharmaceutical partnership • Sponsored Research Agreement
option to license
2 patents: WO2013128137 (A1) & WO 2005115371 (A1)
To conduct the proof of concept in obese and/or
diabetic patients
Contact
To develop the concepts :
Optimization of the beneficial metabolic effects of Béatrice Morio
statins and limitation of some side effects Mel: beatrice.morio@lyon.inra.fr
Tel: +33-4 26 23 59 26
Development of specific pharmaco-nutritional
Christophe Moinard
combinations targeting populations at risk for
obesity and/or type 2 diabetes Mel: christophe.moinard@parisdescartes.fr
Tel: +33-4 76 51 44 90BLUESKY MEETING - SESSION 2
10 octobre 2014, Centre des Congrès WTC - Grenoble
Laurence NAIGLIN, ECOFECT
ECOFECT
Chimeric Mice Core FacilityThe Chimeric Mice Core facility of ECOFECT
Context and Objectives Description
Main objectives of ECOFECT (eco- Chimeric mice can be used as
evolutionary dynamics of infectious diseases) amplification tools of field samples
– To better understand infectious (viruses, etc.)
diseases to better prevent and treat
A Chimeric Mice Core Facility to
infection
facilitate the transfer of field
– To develop interface projects
samples to their exploitation and
between infectiology, ecology,
epidemiology and evolution of
study
interactions Needs:
Cell culture of pathogens from – A high security laboratory animal house
(A3 level) animal facility of Lyon-
patients, the wild fauna or domestic Gerland campus
animals is difficult if not often – Engineers for the development of mouse
impossible models 1 engineer funded by ENSThe Chimeric Mice Core facility of ECOFECT
Originalité scientifique,
Scientific, Technical technique
Assets / & Marchésscientific
Economic ciblés & Retombées
and technical
Innovation
Innovation attendues
impacts expected
Chimeric mice model already The chimeric mice core facility:
developed (F-L Cosset, CIRI): is a potential tool for ECOFECT
mice with a grafted human liver to researchers and the local
amplify and study Hepatitic C and B scientific community
viruses isolated from patients samples will contribute to develop new
Objective : to create other industrial partnerships
chimeric mice models to study will increase the number of
other diseases collaborative projects
– mice with a functional bat liver, will have an impact on
– blood models, employment potential in the
industry through innovation
– etc.The Chimeric Mice Core facility of ECOFECT
Kind ofofpartnership
Kind intended
partnership intended Financial
Financialinstrument considered
instrument considered
Research partnership projects Human ressource costs and bench fees
with industrial partners: funded through collaborative research
– Funding for applied research projects with industrial partners
– CIFRE grants
– Collaborations
Contact
– …
Laurence Naiglin
ecofect@universite-lyon.fr
Tel. 04 72 43 18 05
dominique.pontier@univ-lyon1.fr / flcosset@ens-lyon.frBLUESKY MEETING - SESSION 2
10 octobre 2014, Centre des Congrès WTC - Grenoble
Muriel SALVAT, Grenoble University Hospital
Center
AUTONOM@DOMPilote préfigurateur : AUTONOM@DOM
Contexte
Context et Objectives
and Objectifs Description
Insuffisance cardiaque Patients en perte
chronique
d’autonomie
Télésurveillance
Action / parcours de soins
75 patients équipés vs 75
déplacements inutiles, témoins
les ré H précoces Isère, Paris
le retour a domicilePilote préfigurateur : AUTONOM@DOM
Originalité scientifique, technique & Marchés ciblés & Retombées
Innovation attendues
Etude de faisabilité patients ICC en perte
Télésurveillance d’autonomie
– TA, FC
Hétérogénéité :
– Poids
Evaluation médico-
économique
Décloisonnement médico- – Parcours soins, Re H
social et sanitairePilote préfigurateur : AUTONOM@DOM
Partenariats recherchés
Kind of partnership intended Dispositif de financement
Financial instrument ciblé
considered
Télésurveillance Décret télémédecine
e-learning des personnes Initiative régionale (ARS)
du médico-social et du Innovation technologique
sanitaire
Contact
– Pathologie , fragilité
– Travail en réseau MSalvat@chu-grenoble.fr
Partage de l’info 04 76 76 94 96
partenaire privé (PME)BLUESKY MEETING - SESSION 2
10 octobre 2014, Centre des Congrès WTC - Grenoble
Alice NICOLAS, CEA Grenoble
MODELAST
Cell sensitivity to the elastic properties of the
extracellular matrixModElast
MecaChips:Chemo-mechanical biochips
Context and Objectives Description
Biological cells feel and respond to the rigidity of substrate Chemo-mechanical biochip elaboration (patent)
Objectives: use this mechanosensitivity property to:
– Confine Catalyzed photolithography (µm up to mm resolution )
– Guide
– Sort Controlled functionnalization of biochip surface
– Differentiate cells
Fn Fn Fn Fn Fn
Fn Fn Fn Fn Fn
Fn Fn Fn Fn Fn
Using novel chemo-mechanical biochips mimicking the id ft
Rig So Covalent grafting
rigidity of different human organs / tissues hydrogelModElast
MecaChips:Chemo-mechanical biochips
Originalité scientifique,
Scientific, Technical technique
Assets / & Marchésscientific
Economic ciblés & Retombées
and technical
Innovation
Innovation attendues
impacts expected
Single cell confinement on rigid pattern MecaChips: promising tools to:
Tackle mechanims at the basis of cell mechanosensitivity
Measure cell migration
– Cell separation based on migration rate
– Screening of anti-migratory drugs for cancer cells
Linear cell motion along rigid stripes Improve in vitro pluripotent stem cell differentiation
For regenerative medecine (heart, brain)
Studies performed in strict-controlled, mechanical and
biological conditions
In environment mimicking the rigidity and the
biochemical composition of human tissues/organsModElast
MecaChips:Chemo-mechanical biochips
Kind ofofpartnership
Kind intended
partnership intended Financial
Financialinstrument considered
instrument considered
Conception and production of MecaChips for Project supported by the CEA transversal
specific applications in partnership with
biotechnological companies program « Techno pour la santé »
Creation of a start-up envisioned at the end of
Major targeted applications: 2016
– Stem cell differentiation for restorative
therapeutic approaches in
Contact
Cardiology
Neurology Alice Nicolas LTM: alice.nicolas@cea.fr
Danielle Gulino: danielle.gulino@cea.fr
– Drug screening on cancer cells based on
inhibition of cell migration for
New personalized treatmentsBLUESKY MEETING - SESSION 2
10 octobre 2014, Centre des Congrès WTC - Grenoble
Michel OVIZE, OPeRa IHU
OPeRa BIOBANK
OPeRa (Organ Protection & Remplacement)OPeRa Biobank
Context and Objectives Description
OPeRa:
– PIA (ANR + private partners)
– Consortium of basic science labs and
clinical departments (Nutrition,
Inflammation, Cardiovascular, Transplantation
& Regen.Med., Hepatitis, Imaging)
Our Objectives:
– New biomarkers for diag. and prog.
– clinical + imaging + biological
phenotyping of patients
– Therapeutic innovation « at the
frontiers » of classical medical fields
– Bring material to additional projectsOPeRa Biobank
Originalité scientifique,
Scientific, Technical technique
Assets / & Marchésscientific
Economic ciblés & Retombées
and technical
Innovation
Innovation attendues
impacts expected
- Basic research : up-to-date research Bringing high quality human
in the fields / new markers material for new research
(technical development, handling
- Access to the patients:
- Cohorts / Networks (« à la demande ») of complex information, softwares,
- Database background for large populations
studies (networks),…)
- High quality biological sampling
- Bio-collections in CRB New diagnostic and prognosis tools
Therapeutic innovation (specific
- Accelerated transfer to the clinics
- Know-how clinical research (CIC) candidate to be tested)OPeRa Biobank
Kind ofofpartnership
Kind intended
partnership intended Financial
Financialinstrument considered
instrument considered
OPeRa is a consortium (ANR, Likewise any public-private
HCL, UCBL1, Inserm, CNRS, partnership
private partners) From limited-bilateral (e.g. FUI) to
much larger (e.g. H2020)
Partnership may be: Contact
– Global (> 3 yr RD program)
– Specific bilateral (single research kathleen.terpend@chu-lyon.fr (project
action) manager)
michel.ovize@chu-lyon.frBLUESKY MEETING - SESSION 2
10 octobre 2014, Centre des Congrès WTC - Grenoble
Asbed KECHICHIAN, KeepCleanHands
KCHKeepCleanHands
Contexte
Context et Objectives
and Objectifs Description
Lutte contre infections KCH = solution pour
nosocomiales (IAS)
désinfection
50 à 80% des IAS sont
causées par mauvaise instantanée +
hygiène des mains. protection de
IAS tuent 37 000 longue durée contre
personnes / an en U.E. microbes et virusKeepCleanHands
Originalité scientifique, technique & Marchés ciblés & Retombées
Innovation attendues
Une lotion permettant Traitement rapide et
une protection 20 fois
parfait des mains =
+ longue que les gels
& + de temps & qualité
Un appareil pour une pour soin des patients
parfaite désinfection Coûts IAS en U.E =
des mains, qui qualifie 5,5 milliards € / an
et trace les opérationsKeepCleanHands
Partenariats recherchés
Kind of partnership intended Dispositif de financement
Financial instrument ciblé
considered
Partenariats financiers Appels a projets nationaux,
Développement de Européens
l’appareil :
Mécatronique, Contact
Pulvérisation, akechichian@keepcleanhands.com
Electronique.
Accès au marchéBLUESKY MEETING - SESSION 2
10 octobre 2014, Centre des Congrès WTC - Grenoble
Samy Andrea STROLA, CEA Grenoble
HISTORAM - CEA / LETI / DTBS / STD / LISA
Histopathology via Raman SpectroscopyHISTORAM
Histopathology via Raman Spectroscopy
Context and Objectives Description
To help the pathologist on having a Multimodal platform: a double
rapid diagnostic and a complementary imaging system (wide angle and 20x)
analysis tool in oncology combined with Raman Spectroscopy
Raman Imaging: localization of the
To overcome the limitations of the
existent analysis techniques, reducing cancer with defining the resection
time-consuming processes, expensive margins and cancer classification via
procedures and bulky instruments the specific biochemical fingerprint
Low-cost, user-friendly, compact and
To propose this platform as reliable high-performance solution
instrument improving the work flow
of the pathologist for the cancer
diagnosticHISTORAM
Histopathology via Raman Spectroscopy
Originalité scientifique,
Scientific, Technical technique
Assets / & Marchésscientific
Economic ciblés & Retombées
and technical
Innovation
Innovation attendues
impacts expected
Advantages of Raman Spectroscopy Economic: reduction of the overall
technique cost for the analysis of biopsies
Biochemical mapping Scientific: potential strong impact for
Innovative diagnostic platform for the scientific community and
routine application in the hospitals possibility of IP
and analysis laboratories Technical: democratization of Raman
New reliable instrument for a rapid Spectroscopy that has a great
cancer diagnosis, both for ex-vivo and
potential as new tools for diagnostic
for in-vitro applications
applications
To address the treatment fasterHISTORAM
Histopathology via Raman Spectroscopy
Kind ofofpartnership
Kind intended
partnership intended Financial
Financialinstrument considered
instrument considered
To obtain the collaboration in the Public funding: INCa, BPI, ANR, CLARA
scientific and medical community
(KOL’s) Private: Analysis LABs, Research
Centres on Cancer, Private Investors
To collaborate validating the
approach and obtaining direct
feedback Contact
To strength and optimize the Samy Andrea Strola, PhD
technology proposed CEA Grenoble
LETI / DTBS / STD / LISA
samyandrea.strola@cea.fr ;
phone: 0438782758BLUESKY MEETING - SESSION 2
10 octobre 2014, Centre des Congrès WTC - Grenoble
Thomas CROUZIER
Grenoble Institute of Technology
APIOS
Osteoinductive coatingsAPIOS: Bioactive films for bone regeneration
Context and Objectives Description
Bone Morphogenetic Protein
5 % of bone Bone healing
fractures do not heal Expensive
Uncontrolled deliveryAPIOS: Bioactive films for bone regeneration
Originalité scientifique,
Scientific, Technical technique
Assets / & Marchésscientific
Economic ciblés & Retombées
and technical
Innovation
Innovation attendues
impacts expected
implant BMP Without
+
With
Enhances bone healing
Cheaper
Controlled deliveryAPIOS: Bioactive films for bone regeneration
Kind ofofpartnership
Kind intended
partnership intended Financial
Financialinstrument considered
instrument considered
New markets for BMP Industrial partnership
producers European project
Expend the product line of
orthopedic implant Contact
manufacturers
Catherine.picart@grenoble-inp.frJOURNÉES COLLABORATIVES 10 OCTOBRE 2014 – WTC DE GRENOBLE
PROGRAMME
10 octobre 2014, Centre des Congrès WTC - Grenoble
14H – 16H
8H30
BlueSky session 1 :
Accueil des participants
offres technologiques innovantes
Atrium
Amphithéâtre
9H - 10
Stimuler l’innovation : l’accompagnement BlueSky session 2 :
de Lyonbiopôle idées de projets R&D
Amphithéâtre
Amphithéâtre
10H - 12H45 16H – 17H
Tables rondes de brainstorming Débat : Stratégies d’open innovation
Amphithéâtre et de R&D partenariale
12H45 – 14H des grands groupes
Amphithéâtre
Pause déjeuner
Atrium 17h
Conclusion de la journée
17H30 - 19H30
Cocktail de Networking
AtriumDÉBAT : STRATÉGIES DE PARTENARIAT R&D DES GRANDS GROUPES
10 octobre 2014, Centre des Congrès WTC - Grenoble
Animé par Martin DUVAL
Président et COO
Bluenove Group
Stéphane BOUCHARD Bruno LACROIX Isabelle FUGIER
Président Senior Director, Responsable France R&D
BD France Technology Research Department Network & initiatives
bioMérieux Sanofi PasteurL’Institut Mérieux
Mérieux Institut Transversal Programs Broad and balanced coverage IM missions Added value (synergies, comprehensiveness) Concrete collaborations (modular organization) identified in a concerted manner in line with companies core business Promote emergence of new topics implemented afterwards through collaborative consortia (long term vision) Leverage (external funding) Coordination with internal/external networking and animation (workshops, MRG…)
Mérieux Research Grants
1. Promote emergence of novel research
concepts and their industrial transfer (infectious
Objectives diseases, cancer, nutrisciences)
2. Strengthen international partnerships
2-yr grants : 40-60 to 100-200 k€
Light selection / follow-up
Format
IP rights : ROFR
Attendance 2-day annual meetingMRG: a global network of grantees
80 recipients
60 institutes
16 countries
35
23
22La R&D bioMérieux
• 18 centres de R&D Innovation:
• 100 personnes
• ~ 1 400 collaborateurs • 12M€ budget annuel
• 20-40 « projets »
• ~ 12 % du CA investis en R&D
France* :
9 sites
San Diego Durham
Florence Shanghai
Saint-Louis
Hyderabad
Rio de Janeiro
* Sites R&D en France :
bioMérieux : Marcy, Grenoble, Craponne, La Balme, Verniolle
AES : Combourg, Saint Brieuc, Ker Lann (Rennes), IvryLes Partenaires de bioMérieux pour
l’Innovation
70 collaborations
dans 12 paysLe MALDI-TOF: une innovation de
rupture en microbiologie
2005
Bruker
Daltonics
launches
MALDI
Biotyper november
2011 december august 2013
VITEK MS 2012 2013
Bruker
2010 launched in VITEK MS Biotyper
Europe, Vitek MS
FDA cleared FDA cleared
bioMérieux ASPAC, filed for FDA
for GP and for GN
acquires Canada clearance
GN bacteria bacteria
assets from only
Anagnostec
and partners
with
2009 Shimadzu
1998
bioMérieux
Anagnostec starts
starts developping
developping its own
SARAMIS MALDI-TOF
databaseLa spectrométrie de masse
< < C : \ D o k u m e n t e u n d E in s t e lu n g e n \ m . e r h a r d \ E ig e n e D a t e ie n \ A n a g n o s T e c - d c \ Z w is c h e n a b la g e \ D o k u m e n t B a n n e r . t x t > > S p e c [ B P = 3
3775
100
1648.1
7075
90
10939
8074
8744
80
9453
9994
70
7980
% In ten sity
10347
60
5015
50
7863
11572
40
7092
5931
9654
3581
6837
10226
30
9330
10608
11906
7367
8450
20
10
0
3000 5000 7000 9000 11000 13000
Mass (m/z)La spectrométrie de masse
1. Source 2. Analyzer 3. Detector
•Electrospray Ionization (ESI) •Quadrupoles •Electron Multiplier
•Nano Electrospray Ionization •Quadrupole Ion Trap •Faraday Cup
(NanoESI) •Linear Ion Trap •Photomultiplier
•Atmospheric Pressure Chemical •Ion Trap Limitations Conversion Dynode
Ionization (APCI) •Magnetic Sector •Array Detector
•Atmospheric Pressure Photo •Time-Of-Flight (TOF) •Charge (or Inductive)
Ionization (APPI) •Fourier Transform Mass Detector
•Matrix-Assisted Spectrometry (FTMS)
Desorption/Ionization (MALDI) •Orbitrap
•Desorption/Ionization on Silicon
(DIOS)
•Fast Atom/Ion Bombardment (FAB)
•Electron Ionization (EI)
•Chemical Ionization (CI) MALDI TOF: pour l’identification bactérienne
1. Source 2. Analyzer
Matrix-Assisted
Time-Of-Flight
Desorption/Ionizat
Analysis (TOF)
ion (MALDI)Etapes clés du développement de bioMérieux
1963 1973 1986 1988 1992 1996 1998 2001 2004 2006 2007 2008 2010 2011 2012 2013
50 ans d’expertise dans le diagnostic in vitro 58Medical Device Development vs Technology
Readiness LevelsLa spectrométrie de masse
1. Source 2. Analyzer 3. Detector
•Electrospray Ionization (ESI) •Quadrupoles •Electron Multiplier
•Nano Electrospray Ionization •Quadrupole Ion Trap •Faraday Cup
(NanoESI) •Linear Ion Trap •Photomultiplier
•Atmospheric Pressure Chemical •Ion Trap Limitations Conversion Dynode
Ionization (APCI) •Magnetic Sector •Array Detector
•Atmospheric Pressure Photo •Time-Of-Flight (TOF) •Charge (or Inductive)
Ionization (APPI) •Fourier Transform Mass Detector
•Matrix-Assisted Spectrometry (FTMS)
Desorption/Ionization (MALDI) •Orbitrap
•Desorption/Ionization on Silicon
(DIOS)
•Fast Atom/Ion Bombardment (FAB)
•Electron Ionization (EI)
< < C : \ D o k u m e n t e u n d E in s t e lu n g e n \ m . e r h a r d \ E ig e n e D a t e ie n \ A n a g n o s T e c - d c \ Z w is c h e n a b la g e \ D o k u m e n t B a n n e r . t x t > > S p e c [ B P = 3
3775
•Chemical Ionization (CI) MALDI TOF: pour l’identification bactérienne
100
1648.1
7075
90
10939
8074
8744
80
9453
9994
70
7980
% In ten sity
10347
60
5015
50
7863
11572
40
7092
5931
9654
3581
6837
10226
30
9330
10608
11906
7367
8450
20
10
0
1. Source 3000
2. Analyzer
5000 7000
Mass (m/z)
9000 11000 13000
Matrix-Assisted
Time-Of-Flight
Desorption/Ionizat
Analysis (TOF)
ion (MALDI)Le MALDI-TOF: une innovation de
rupture en microbiologie
2005
Bruker
Daltonics
launches
MALDI
Biotyper november
2011 december august 2013
VITEK MS 2012 2013
Bruker
2010 launched in VITEK MS Biotyper
Europe, Vitek MS
FDA cleared FDA cleared
bioMérieux ASPAC, filed for FDA
for GP and for GN
acquires Canada clearance
GN bacteria bacteria
assets from only
Anagnostec
and partners
with
2009 Shimadzu
1998
bioMérieux
Anagnostec starts
starts developping
developping its own
SARAMIS MALDI-TOF
databaseL’Innovation à bioMérieux
• Equipe pluridisciplinaire de 100 personnes (France et US)
– biologie (microbiologie, biologie moléculaire,
protéomique)
– biomathématique/bioinformatique
– automatique
– biophysique
– biophotonique
– microfluidique
• Missions
– Détecter les opportunités technologiques par uneCycle de vie et parties prenantes d’un
produit IVD
industriels
produit IVD = HW+SW+consommables+réactifs
haute technologie
sciences de la vie
IVD agences
règlementaires
développement
laboratoires évaluation (clinique
innovation
cliniciens et économique)
technologie
besoins
recherche commercialisation
académique payeurs
patientsYou can also read
